(Q39474173)

12 September 2017

1 reference

title

Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia (English)

1 reference

12 September 2017

W H Frishman

1

1 reference

12 September 2017

1 September 1988

1 reference

Cardiovascular Drugs and Therapy

12 September 2017

1 reference

12 September 2017

2

1 reference

12 September 2017

3

1 reference

12 September 2017

343-353

1 reference

Comparison of labetalol with other anti-hypertensive drugs

12 September 2017

1 reference

https://api.crossref.org/works/10.1007%2FBF00054642

Labetalol in general practice: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00054642

Comparison of labetalol and propranolol in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00054642

Rapid onset of action of oral labetalol in severe hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00054642

Rapid reduction of blood pressure with acute oral labetalol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00054642

Review of long-term treatment with labetalol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00054642

The use of labetalol in Japan: results of multicentre clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00054642

Clinical investigation of an antagonist at alpha- and beta-adrenoceptors-AH5158A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00054642

A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug

21 January 2018

1 reference

12 December 2020

Monotherapy with labetalol in the treatment of mild hypertension: A double-blind study

1 reference

12 December 2020

Labetalol possesses beta-adrenoceptor agonist action on the rat isolated uterus

1 reference

12 December 2020

Hemodynamic and coronary effects of intravenous labetalol in coronary artery disease.

1 reference

12 December 2020

A controlled trial of labetalol (Trandate), propranolol and placebo in the management of mild to moderate hypertension

1 reference

12 December 2020

Preliminary studies of the pharmacological effects of 5-[1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)-ethyl] salicylamide (AH 5158) in man

1 reference

12 December 2020

Labetalol: potent antihypertensive agent that blocks both alpha- and beta-adrenergic receptors

1 reference

12 December 2020

Clinical evaluation of labetalol alone and combined with chlorthalidone in essential hypertension: a double-blind multicentre controlled study

1 reference

12 December 2020

Antimitochondrial antibodies associated with labetalol

1 reference

12 December 2020

The Relationships Between the Cardiovascular Effects, α- and β-Adrenoceptor Blocking Actions and Plasma Concentration of Labetalol in Doca Hypertensive Rats

1 reference

12 December 2020

The effects of a new alpha- and beta-adrenoceptor antagonist (AH5158) upon the general and coronary haemodynamics of intact dogs

1 reference

12 December 2020

Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors

1 reference

12 December 2020

Labetalol: a review of its pharmacology and therapeutic use in hypertension

1 reference

12 December 2020

The pharmacology of labetalol, an α- and β-adrenoceptor blocking agent

1 reference

12 December 2020

Beta-adrenoceptor agonist activity of labetolol on the isolated uterus of the rat

1 reference

12 December 2020

Alpha and beta adrenoceptor blocking properties of labetalol and its R,R-isomer, SCH 19927

1 reference

12 December 2020

Alpha-Adrenergic Receptor Subtypes

1 reference

12 December 2020

Step II treatment with labetalol for essential hypertension

1 reference

12 December 2020

Adrenoceptor blockade of the circulatory responses to intravenous isoproterenol

1 reference

12 December 2020

Labetalol and bendrofluazide: comparison of their antihypertensive effects

1 reference

12 December 2020

Systemic and coronary hemodynamic effects of combined alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress test responses

1 reference

12 December 2020

Left ventricular hypertrophy in hypertension and the effects of antihypertensive drug therapy

1 reference

12 December 2020

Cutaneous reaction to labetalol

1 reference

12 December 2020

The effects of oral AH 5158, a combined α and β-adrenoceptor antagonist, in healthy volunteers

1 reference

12 December 2020

Labetalol: A Review of Its Pharmacology, Pharmacokinetics, Clinical Uses and Adverse Effects

1 reference

12 December 2020

Comparison of effects on cerebral blood flow of rapid reduction in systemic arterial pressure by diazoxide and labetalol in hypertensive patients: preliminary findings

1 reference

12 December 2020

Hemodynamic Changes After Acute and Long-Term Combined Alpha—Beta-Adrenoceptor Blockade with Labetalol as Compared with Beta-Receptor Blockade

1 reference

12 December 2020

Systemic and coronary hemodynamics of labetalol in normotensive patients with ischemic heart disease.

1 reference

12 December 2020

Labetalol in long-term treatment of hypertension

1 reference

12 December 2020

The acute and chronic hypotensive effect of labetalol and the relationship with pretreatment plasma noradrenaline levels

1 reference

12 December 2020

The alpha- and beta-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues

1 reference

12 December 2020

Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol

1 reference

12 December 2020

Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydrallazine, and diazoxide: the use of AH 5158 in the treatment of hypertension

1 reference

12 December 2020

Effect of an alpha- and beta-adrenoceptor-blocking agent (labetalol) on haemodynamics in hypertension

1 reference

12 December 2020

Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 7. New horizons in beta-adrenoceptor blockade therapy: Labetalol

1 reference

12 December 2020

Alpha- and beta-adrenergic receptor blockade in the treatment of hypertension

1 reference

12 December 2020

Labetalol in resistant hypertension

1 reference

12 December 2020

Double-blind trial of labetalol

1 reference

12 December 2020

Postsynaptic alpha 1- and alpha 2-adrenergic mechanisms in coronary vasoconstriction.

1 reference

12 December 2020

Combined alpha- and beta-adrenoceptor blockade with labetalol in hypertension

1 reference

12 December 2020

Labetalol compared with propranolol in the treatment of black hypertensive patients

1 reference

12 December 2020

Anti-mitochondrial antibodies associated with labetalol

1 reference

12 December 2020

Direct vasodilatation by labetalol in anaesthetized dogs

1 reference

12 December 2020

Anti-hypertensive action, time of onset and effects on carbohydrate metabolism of labetalol

1 reference

12 December 2020

Response of the systemic and pulmonary circulation to alpha- and beta-receptor blockade (labetalol) at rest and during exercise in hypertensive patients

1 reference

12 December 2020

Labetalol and propranolol in mild hypertensives: comparison of blood pressure and plasma volume effects

1 reference

12 December 2020

Circulatory effects of noradrenaline and adrenaline before and after labetalol

1 reference

12 December 2020

A comparison of the effects of labetalol, bendrofluazide and their combination in hypertension

1 reference

12 December 2020

A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension

1 reference

12 December 2020

Acute haemodynamic effects of labetalol and its subsequent use of an oral hypotensive agent

1 reference

12 December 2020

Labetalol in Essential Hypertension

1 reference

12 December 2020

Alpha- and beta-adrenoceptor blocking actions of labetalol and effects on the myocardial function, coronary circulation and myocardial energy metabolism thereof (author's transl)

1 reference

12 December 2020

N-Aralkyl substitution increases the affinity of adrenergic drugs for the alpha-adrenoceptor in rat liver

1 reference

12 December 2020

Sequential haemodynamic effects of labetalol at rest and during exercise in essential hypertension.

1 reference

12 December 2020

Acute Hemodynamic Effects of Labetalol in Severe Hypertension

1 reference

12 December 2020

Antihypertensive and hemodynamic actions of SCH 19927, the R,R-isomer and labetalol

1 reference

12 December 2020

Pharmacological basis for antihypertensive effects of intravenous labetalol

1 reference

12 December 2020

Labetalol in normotensive patients with angina pectoris

1 reference

12 December 2020

Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects

1 reference

12 December 2020

Pharmacological effects of labetalol in man

1 reference

12 December 2020

Modification of pressor responses induced by 'cold' [proceedings]

1 reference

12 December 2020

Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension

1 reference

12 December 2020

The effects of labetalol (AH 5158) on adrenergic transmission in the cat spleen

1 reference

12 December 2020

Labetalol therapy in patients with systemic hypertension and angina pectoris: effects of combined alpha and beta adrenoceptor blockade

1 reference

12 December 2020

Short- and long-term (six-year) hemodynamic effects of labetalol in essential hypertension.

1 reference

12 December 2020

Labetalol. Current research and therapeutic status

1 reference

12 December 2020

Lupus-type illness associated with labetalol

1 reference

12 December 2020

Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina

1 reference

12 December 2020

Pharmacology of labetalol in experimental animals

1 reference

12 December 2020

Comparative haemodynamic effects of labetalol, timolol, prazosin and the combination of tolamolol and prazosin

1 reference

12 December 2020

Haemodynamic effects of long-term oral labetalol

1 reference

12 December 2020

Cardiovascular dynamics after acute and long-term alpha- and beta-adrenoceptor blockade at rest, supine and standing, and during exercise

1 reference

12 December 2020

Labetalol and alprenolol. A comparative investigation of antihypertensive effect

1 reference

12 December 2020

Labetalol and pindolol in the treatment of hypertension: a comparative study

1 reference

12 December 2020

Controlled comparison of labetalol and propranolol in the management of severe hypertension

1 reference

12 December 2020

Intrinsic activity of labetalol on guinea-pig isolated trachea

1 reference

12 December 2020

Immediate effects of labetalol on central, splanchnic-hepatic, and forearm haemodynamics during pleasant emotional stress in hypertensive patients.

1 reference

12 December 2020

Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies

1 reference

12 December 2020

Relationship between plasma concentrations and pharmacological effects of labetalol

1 reference

12 December 2020

Labetalol-induced Peyronie's disease? A case report

1 reference

12 December 2020

Bullous lichen planus caused by labetalol

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00054642

1 reference

release_m3nodep7zzceldqhbn2h6ziit4

12 September 2017

0 references

PubMed ID

2908732

1 reference

PubMed ID

2908732